Key points: Ramadan brings unique mental health challenges surrounding fasting, sleep, and medication needs. Clinicians and employers need to provide tailored care addressing Ramadan’s challenges for mental health. Culturally aware care improves Ramadan mental health; understanding fasting’s impact is key. Support for mood swings, sleep loss, and medication adjustments can improve mental health during Ramadan.

As recent research has shown, women and girls with attention-deficit/hyperactivity disorder (ADHD) go undiagnosed longer than boys and men. A new mixed-methods study published in the Journal of Attention Disorders confirms this research and investigates the barriers to care women diagnosed with ADHD face, as well as what practical changes clinicians can make to create…

A study examining how working memory in children with ADHD varies with the use of stimulant medication found that these medications improve working memory. Both phonological and visuospatial working memory were better when children took medication and were more physically active during memory tasks. The effects of the medications on visuospatial memory were strongest in…

A new study from Brazil has shed light on the complex origins of attention-deficit hyperactivity disorder, commonly known as ADHD. Researchers discovered that both a person’s genetic predisposition for ADHD and experiences of childhood maltreatment independently increase the likelihood of experiencing ADHD symptoms in adulthood. Furthermore, the study suggests that genetic factors that raise the…

Study suggests starting on stimulants via a virtual visit largely doesn’t lead to more substance use disorder, except in young adults; better screening and ongoing monitoring needed for all ages

Adults with disabilities are nearly twice as likely to misuse prescription drugs as adults without disabilities, according to West Virginia University research. Jeanette Garcia, associate professor at the WVU College of Applied Human Sciences, said the findings point to the urgency of curbing prescription misuse among adults with disabilities.

A new research report shows that 1 in 5 people using drugs and alcohol have symptoms of ADHD and that this rate increases to over one-third among people using benzodiazepines. The report—launched at a seminar this morning in Dublin’s Wynn’s Hotel—also shows that the highest rates of ADHD overall were found among women using these…

Cingulate Inc. (NASDAQ: CING) has released Phase 3 safety data for CTx-1301 (dexmethylphenidate), a once-daily stimulant medication designed to provide full-day efficacy for individuals with Attention Deficit Hyperactivity Disorder (ADHD).1,2 The data, which includes results from 2 pediatric and adolescent studies, will support the company’s New Drug Application (NDA) submission to the FDA, expected to…

Summary: New research reveals that a mother’s diet during pregnancy — characterized by a Western dietary pattern high in fat and sugar and low in fresh ingredients — may increase the risk of neurodevelopmental conditions such as ADHD and autism in children. Researchers see potential for targeted dietary interventions during pregnancy to reduce this risk.

An estimated 22 million adults and children in the U.S. suffer from ADHD. The patient population is diverse, made up of people from all ethnicities, gender identities, and ages. However, for as long as the medical community has recognized ADHD, there has been skepticism and misunderstanding of this disorder in the Black community.

New research published in the Journal of Attention Disorders reveals a significant increase in the number of working-age adults in the United States who report having ever been diagnosed with attention-deficit/hyperactivity disorder, or ADHD. The study found that nearly 14% of adults between the ages of 18 and 64 reported a past diagnosis, a figure…

Glenmark Pharma, an India-based drug manufacturer that has been the focal point of a spate of recalls in recent years, has issued another. This time, the product pull covers about 1.48 million bottles of the generic attention deficit hyperactivity disorder (ADHD) drug atomoxetine.